Cue Biopharma Long Term Debt

As of the most recent data (March 2026), CUE shows a long-term debt of $1.9M. That compares with $180K in the prior-year period — up 967.0% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, CUE's long-term debt is now $1.9M (was $180K) — a 967.0% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Cue Biopharma is outperforming or lagging.

Tracking CUE's long-term debt over time shows whether Cue Biopharma is scaling, shrinking, or reshaping that part of the business. The current reading is $1.9M That compares with $180K in the prior-year period — up 967.0% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this long-term debt page, Stockcircle has Cue Biopharma's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect long-term debt (currently $1.9M) with ownership activity and broader fundamentals.

Cue Biopharma's long-term debt is $1.9M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.